Adalvo Announces successful DCP closure for Fulvestrant pre-filled injection

Adalvo is pleased to announce our successful DCP closure for Fulvestrant pre-filled injection.

Adalvos product is a fully EU compliant generic version of Faslodex, which is a widely used drug, indicated in estrogen receptor positive, locally advanced, or metastatic breast cancer, in postmenopausal women. This product is very complientary to the broad oncology portfolio of Adalvo and creates additional synergies for our existing partners in the market. The product sold at around $712 million in 2021, according to IQVIA.

While Fulvestrant generics are available in Europe, Adalvo and its partners believe that this positive progress, combined with competitive manufacturing of the product, and Adalvo's wide network of strategic partners, are the basis for a solid product launch.

For further information visit Adalvos Newsroom.